Navigation Links
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
Date:4/10/2008

ogens provides additional support and confidence to the mechanistic rationale for treating diarrhea in patients with different causes. In conjunction with the on-going Phase 3 trial that Napo is conducting in chronic diarrhea in people living with HIV/AIDS, this Glenmark trial will provide a new pathway to a therapy for both acute and chronic secretory diarrhea. Glenmark expects to file for approval of crofelemer for the CRO-ID indication in India in 2009, and, in combination with Napo's NDA programs for crofelemer, the various approvals may allow for subsequent approvals in the multiple countries where Glenmark is a licensee."

For more information please contact:

Napo Pharmaceuticals, Inc.

Lisa Conte, Chief Executive Officer

(001) + 650 616 1902

Charles Thompson, Chief Financial Officer

(001) + 650 616 1903

Buchanan Communications

(44) + 020 7466 5000

Tim Anderson, Mary-Jane Johnson

About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. Napo was founded in November 2001, and is based in California, USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in various stages of clinical development for four distinct product indications, including a late-stage Phase 3 program:
-- CRO-HIV for AIDS diarrhea, Phase 3

-- CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2

-- CRO-ID for acute infectious diarrhea (including cholera), Phase 2

-- CRO-PED for pediatric diarrhea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to deve
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. Medarex Announces Ipilimumab Program Continues to Move Forward
11. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced ... for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced ... in vivo antitumor activity and a favorable safety ... in clinical development. The trials will be performed ...
... Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the quarter ended December 31, 2010. ... ended December 31, 2010 compared to $0.3 million for ...
Cached Medicine Technology:PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6
(Date:7/28/2014)... July 29, 2014 “China Surgical ... data on the China Surgical Generators market. The ... volume (in units) and average prices (in US ... Generators, Ultrasonic Generators and Argon Plasma Coagulation Generators. ... distribution shares data for each of these market ...
(Date:7/28/2014)... Heights, MI (PRWEB) July 28, 2014 ... UHY, introduces the latest edition of UHY International Business ... provided by our members, on the most current business ... around the world. Issue 29 covers the following topics:, ... growth: Which industry sectors will thrive over the next ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... July 28, 2014 Thousands of DePuy ... behalf of individuals who were allegedly injured by a ... to move forward in U.S. District Court, Northern District ... Order issued on July 18, 2014, U.S. District Judge ... by the Plaintiffs’ Steering Committee that sought the deposition ...
(Date:7/28/2014)... Ticket Down is a dependable source for cheap ... the Sun Life Stadium in early September. The decades ... has is one that has continues to go on. With ... a consistent basis. The rivalry between South America nations, ... 2014 World Cup. To the delight of soccer aficionados ...
Breaking Medicine News(10 mins):Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3
... researcher at The University of Texas Health Center at ... of the blood-clotting process works. Once the process// is ... it, thus preventing excessive bleeding or blood clotting. The ... published in the Aug. 11, 2006, edition of the ...
... tuberculosis, precautionary letters have been sent to 500 people ... the// disease. The condition of the patient suffering ... ,The patient was diagnosed with active form ... diseases unit at Aberdeen Royal Infirmary from Aberdeen's Woodend ...
... who advice patients to give up smoking may be more ... according to a new study in the July-August 2006// Nursing ... recognized as central to global efforts to reduce the detrimental ... Nursing Research editor and professor of nursing at the University ...
... An MRI-guided breast biopsy successfully removed the breast lesion ... slices of the lesion, according to radiologists. "Contrast-enhanced// MRI ... with lesions that cannot be detected with other techniques," ... the University of Texas M.D. Anderson Cancer Center in ...
... as a hazard of aging, but researchers actually do ... aging// or not. Researchers at the Salk Institute for ... conducted a study that proves it is aging that ... beta amyloid aggregates accumulate when aging impedes two molecular ...
... Dr. Morey Haymond, chief of paediatric endocrinology at Texas Children's ... tale signs of diabetes in children. , ,Children ... a bit more independent, hence parents many not be able ... 2 diabetes is more an affliction with the obese and ...
Cached Medicine News:Health News:Scientist Discovers Crucial Part of Blood-Clotting Process 2Health News:Nurses Can Play Big Role In Helping Patients Quit Smoking 2Health News:MRI-guided Breast Biopsy Pronounced a Success 2Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medpor 2/3 Orbit implants are designed to replace non load bearing bony structures in the orbital area....
Medicine Products: